Loxapine film - IntelGenx

Drug Profile

Loxapine film - IntelGenx

Alternative Names: CNS Versafilm™ therapeutic; INT 0036/2012; INT 0036/2013; INT0036

Latest Information Update: 12 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IntelGenx Corp.
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Schizophrenia
  • Preclinical CNS disorders

Most Recent Events

  • 10 Feb 2016 IntelGenx files for patent protection with US PTO for loxapine oral film
  • 03 Nov 2014 Clinical trials in Schizophrenia in Canada (PO) before November 2014
  • 03 Nov 2014 Pharmacokinetics data from a pilot clinical trial in Schizophrenia released by IntelGenx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top